Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Immunomedics Inc (NASDAQ:IMMU)

2.25
Delayed Data
As of 4:00pm ET
 +0.07 / +3.21%
Today’s Change
1.50
Today|||52-Week Range
5.44
-26.71%
Year-to-Date
Cancer doctors face next drug challenge
Jun 01 / FT.com - Paid Partner Content
 

Today’s Trading

Previous close2.18
Today’s open2.19
Day’s range2.11 - 2.28
Volume2,352,624
Average volume (3 months)1,865,678
Market cap$206.7M
Dividend yield--
Data as of 4:00pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)-21.43%
Earnings growth (this year)-8.82%
Earnings growth (next 5 years)+20.00%
Revenue growth (last year)-37.48%
P/E ratioNM
Price/Sales67.02
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AXGNAxoGen Inc+0.07+1.06%
EARSAuris Medical Holdin...0.000.00%
IRIXIRIDEX Corp+0.33+2.28%
CUTRCutera Inc+0.16+1.48%
Data as of 4:00pm ET, 06/29/2016

Financials

Next reporting dateAugust 18, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$5.7M
Annual profit (last year)-$48.0M
Net profit margin-849.13%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, Chief Scientific &
Patent Officer
David M. Goldenberg
President, Chief Executive Officer &
Director
Cynthia L. Sullivan
Corporate headquarters
Morris Plains, New Jersey

Forecasts

Partner Offers

Search for Jobs